Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347791 | 1.00 | HTR2A (0.31) | HTR2AKCNH2GPR3NFE2L2 | |
| SCHEMBL3775400 | 1.00 | HTR2A (0.31) | HTR2AKCNH2GPR3NFE2L2 | |
| SCHEMBL347790 | 1.00 | HTR2A (0.31) | HTR2AKCNH2GPR3NFE2L2 | |
| SCHEMBL30962424 | 1.00 | HTR2A (0.31) | HTR2AKCNH2GPR3NFE2L2 | |
| SCHEMBL17819857 | 0.83 | CCR1 (0.34) | GPR3 | |
| SCHEMBL17819852 | 0.83 | CCR1 (0.34) | GPR3 | |
| SCHEMBL17819854 | 0.83 | CCR1 (0.34) | GPR3 | |
| SCHEMBL17820395 | 0.83 | CCR1 (0.34) | GPR3 | |
| SCHEMBL17820393 | 0.83 | CCR1 (0.34) | GPR3 | |
| SCHEMBL17819848 | 0.83 | CCR1 (0.34) | GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011545-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-20140155394-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2014-06-05 | — | — | US | disclosed |
| US-8486966-B2 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | ASTRAZENECA AB (SE) | 2013-07-16 | — | — | US | disclosed |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-12-23 | — | — | US | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011545-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | HTR2A 4565/4885KCNH2 3216/4885GPR3 3185/4885 |
| US-20140155394-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | HTR2A 4565/4885KCNH2 3216/4885GPR3 3185/4885 |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | THPO, MPL, MCL1 | HTR2A 1323/4885KCNH2 1842/4885GPR3 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.